CORT
Corcept Therapeutics IncorporatedNASDAQHealthcare$42.49+1.21%ClosedMarket Cap: $4.52B
As of 2026-04-06
Valuation
P/E (TTM)
45.62
PEG
—
P/B
6.81
P/S
5.94
EV/EBITDA
77.11
DCF Value
$104.53
FCF Yield
3.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.3%
Operating Margin
5.9%
Net Margin
13.0%
ROE
15.3%
ROA
11.8%
ROIC
6.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $202.1M | 98.7% | $4.5M | $24.3M | $0.20 | — |
| FY 2025 | $761.4M | 98.3% | $44.8M | $99.7M | $0.82 | — |
| Q3 2025 | $207.6M | 97.8% | $10.2M | $19.4M | $0.16 | — |
| Q2 2025 | $194.4M | 98.2% | $26.7M | $35.1M | $0.29 | — |
| Q1 2025 | $157.2M | 98.5% | $3.4M | $20.3M | $0.17 | — |
| Q4 2024 | $181.9M | 98.4% | $25.3M | $30.4M | $0.26 | — |
| FY 2024 | $675.0M | 98.4% | $137.0M | $139.7M | $1.23 | — |
| Q3 2024 | $182.5M | 98.4% | $46.6M | $46.7M | $0.41 | — |
| Q2 2024 | $163.8M | 98.5% | $35.6M | $35.5M | $0.32 | — |
| Q1 2024 | $146.8M | 98.3% | $29.5M | $27.8M | $0.25 | — |
| Q4 2023 | $135.4M | 98.6% | $31.7M | $31.4M | $0.28 | — |
| FY 2023 | $482.4M | 98.7% | $107.3M | $106.1M | $0.94 | — |